Concluding from the clinical features of 51 pairs of ovarian cancer patients and 49 primary invasive ovarian cancer patients, PRR11 is positively correlated with improved FIGO stage, larger tumor size, more lymph node metastasis and shorter overall survival [7,11]. This evidence concerns the gene PRR11 and neoplasm.